PMID- 35402220
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With 
      Nivolumab and Ipilimumab.
PG  - 806501
LID - 10.3389/fonc.2022.806501 [doi]
LID - 806501
AB  - The development of immune checkpoint inhibitors (ICIs) has greatly improved 
      survival of patients with advanced malignancies. ICIs can cause immune-related 
      adverse effects (irAEs) involving any organ. Neurological irAEs are infrequent 
      and have mostly been reported in patients with melanoma. We describe the case of 
      a 57-year-old male with right eye uveal melanoma, gene expression profile (class 
      2), and PRAME (preferentially expressed antigen in melanoma) positivity, who 
      received plaque brachytherapy with Iodine-125 for 4 days with subsequent adjuvant 
      ICIs (immune checkpoint inhibitors), nivolumab and ipilimumab. 18 weeks after 
      discontinuation of immunotherapy, the patient presented with acute onset of 
      left-sided headaches, pain with eye movements, and vision loss. The patient was 
      tested positive for serum anti-aquaporin-4 antibody (AQP4-Ab) and was diagnosed 
      with neuromyelitis optica spectrum disorder (NMOSD). Subsequently, he was treated 
      with 5 days of intravenous methylprednisolone followed by an oral prednisone 
      taper over 10 weeks, with improvement in symptoms. We report a unique case of 
      neuromyelitis optica spectrum disorder (NMOSD) following treatment with ICIs. To 
      our best knowledge, this is the third reported case in English literature of 
      NMOSD following ICI therapy and the first reported case of NMOSD caused by ICI 
      treatment in uveal melanoma.
CI  - Copyright (c) 2022 Khimani, Patel, Whyte and Al-Zubidi.
FAU - Khimani, Karima
AU  - Khimani K
AD  - Department of Ophthalmology, University of Texas Medical Branch, Galveston, TX, 
      United States.
FAU - Patel, Sapna P
AU  - Patel SP
AD  - Department of Melanoma Medical Oncology, The University of Texas MD Anderson 
      Cancer Center, Houston, TX, United States.
FAU - Whyte, Andrew
AU  - Whyte A
AD  - Department of Head and Neck Surgery, Section of Ophthalmology, The University of 
      Texas MD Anderson Cancer Center, Houston, TX, United States.
FAU - Al-Zubidi, Nagham
AU  - Al-Zubidi N
AD  - Department of Head and Neck Surgery, Section of Ophthalmology, The University of 
      Texas MD Anderson Cancer Center, Houston, TX, United States.
AD  - Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, 
      Houston, TX, United States.
AD  - Department of Ophthalmology, Weill Cornell Medicine, New York, NY, United States.
LA  - eng
PT  - Case Reports
DEP - 20220323
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8984112
OTO - NOTNLM
OT  - NMO
OT  - immune checkpoint inhibitor
OT  - ipilimumab
OT  - neuromyelitis optica spectrum disorder
OT  - nivolumab
OT  - uveal melanoma
COIS- Author SP received institutional clinical trial or research support from Bristol 
      Myers Squibb, Foghorn Therapeutics, InxMed, Novartis, Provectus 
      Biopharmaceuticals, Reata, TriSalus Life Sciences, is on the advisory board for 
      Cardinal Health, Castle Biosciences, and TriSalus Life Sciences, and has provided 
      consulting services for Advance Knowledge in Healthcare and Immunocore. The 
      remaining authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/12 06:00
MHDA- 2022/04/12 06:01
PMCR- 2022/01/01
CRDT- 2022/04/11 05:30
PHST- 2021/10/31 00:00 [received]
PHST- 2022/02/24 00:00 [accepted]
PHST- 2022/04/11 05:30 [entrez]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/04/12 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.806501 [doi]
PST - epublish
SO  - Front Oncol. 2022 Mar 23;12:806501. doi: 10.3389/fonc.2022.806501. eCollection 
      2022.